Supporting cognitive function and neurorecovery processes

Cerebrolysin® is a medicine used in neurology, which contains a hydrolysate of porcine brain protein and acts on the central nervous system.

Through its neurotrophic and neuroprotective properties, Cerebrolysin acts on mechanisms involved in neuronal function, neuroplasticity and neurological recovery processes.

How does Cerebrolysin work?

Cerebrolysin has a multimodal action on the central nervous system, being involved in mechanisms associated with:

supporting neuronal function and metabolism;
neuroplasticity – the brain's capacity to adapt and reorganize;
neuroprotection;
supporting neurorecovery processes after certain brain injuries.

Indications

Cerebrolysin may be used, depending on medical assessment and indication, in:

mild neurocognitive disorder (MCI – Mild Cognitive Impairment);
Alzheimer's disease and associated neurocognitive disorders;
neurocognitive disorders of vascular origin;
stroke, as part of the neurological recovery process;
traumatic brain injury, as part of the neurorecovery process.

Cerebrolysin has been studied in the field of cognitive function and neurocognitive disorders, as well as in neurorecovery processes after stroke and traumatic brain injury.

Clinical studies have evaluated its effects on parameters of memory, attention, global cognitive function and neurological and functional recovery.

Intravenous administration

Cerebrolysin can be administered as an intravenous infusion, in therapeutic courses.

The dose, the duration of the course and the number of administrations are established individually, according to the medical indication, the diagnosis, the clinical condition and the particularities of each patient.

Cerebrolysin therapy at Maison Longévité

At Maison Longévité, intravenous Cerebrolysin therapy is carried out following a medical consultation and after the therapeutic indication has been established.

During the consultation, medical history, neurological and cognitive status, associated conditions, ongoing treatments and the individual particularities of the patient are assessed.

In people who present changes in memory, attention or other cognitive functions, the assessment aims to identify the causes and the factors that may contribute to cognitive decline and to establish an individualized therapeutic approach.

Contraindications

The administration of Cerebrolysin is contraindicated in cases of:

hypersensitivity to the active substance or to any of the components;
epilepsy;
severe renal impairment.

Scientific references

Masliah E, Díez-Tejedor E. The pharmacology of neurotrophic treatment with Cerebrolysin: brain protection and repair to counteract pathologies of acute and chronic neurological disorders. Drugs Today (Barc). 2012;48(Suppl A):3–24.
Gavrilova SI, Alvarez A. Cerebrolysin in the therapy of mild cognitive impairment and dementia due to Alzheimer's disease: 30 years of clinical use. Med Res Rev. 2021;41(5):2775–2803.
Gauthier S, Proaño JV, Jia J, et al. Cerebrolysin in mild-to-moderate Alzheimer's disease: a meta-analysis of randomized controlled clinical trials. Dement Geriatr Cogn Disord. 2015;39(5–6):332–347.
Ghaffarpasand F, et al. Effects of Cerebrolysin on functional outcome of patients with traumatic brain injury: a systematic review and meta-analysis. Neuropsychiatr Dis Treat. 2019;15:127–135.
Vester JC, et al. Cerebrolysin after moderate to severe traumatic brain injury: prospective meta-analysis of the CAPTAIN trial series. Neurol Sci. 2021;42(11):4531–4541.
Ziganshina LE, et al. Cerebrolysin for acute ischaemic stroke. Cochrane Database Syst Rev. 2023;10:CD007026.